NCT01805284View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Pneumonia
Interventions
DRUG

Linezolid

600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.

Trial Locations (1)

9000

Ghent University Hospital, Ghent

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

University Hospital, Ghent

OTHER

collaborator

Pfizer

INDUSTRY

lead

University Ghent

OTHER

NCT01805284 - Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia | Biotech Hunter | Biotech Hunter